Cancer Research · asia
Adding Rare-Earth Ions to Extracellular Vesicles Amplifies Cancer Cells’ “Self-Recognition” Signal by More Than 25-Fold
A research team modified the surfaces of extracellular vesicles with lanthanide ions, greatly improving the speed and selectivity with which cancer cells recognize vesicles from the same source, and detected extremely small numbers of tumor cells in simulated blood samples; however, this diagnostic and delivery concept remains at the stage of cell and animal blood models.
The challenge facing liquid biopsy for cancer is not merely whether tumor signals are present in the blood, but how to reliably isolate them from the vast background of normal cells and vesicles. A study published in *Nature Biomedical Engineering* attempted to amplify cells’ inherent ability to “recognize their own kind”: simply introducing lanthanide metal ions onto the surfaces of small extracellular vesicles can accelerate their return to cells of the same origin.
Extracellular vesicles are nanoscale membrane-bound particles released by cells that carry proteins, lipids, and nucleic acids; the small extracellular vesicles treated in this study were approximately 30 to 150 nanometers in diameter. They generally retain some surface characteristics of their cells of origin and may therefore preferentially interact with similar cells, but their natural homotypic targeting is often insufficiently strong and can easily be overwhelmed in complex biological samples.
The researchers modified vesicle surfaces with europium or terbium ions, using coordination interactions between these ions and sialic acids commonly found on cancer-cell membranes. The study showed that this method amplified the interaction between specific cells and vesicles of the same origin by more than 25-fold; selective capture that might originally have required more than two days was shortened to approximately three hours. Even when samples contained large quantities of vesicles from other sources, cells of the same origin still acquired matching vesicles more quickly, a phenomenon the research team called “super-homotypic targeting.”
This capability can be used in two directions: enabling cells to recognize vesicles from a specific source within a mixture, or, conversely, using engineered vesicles to find cells of the same lineage. The former may help distinguish vesicles released by tumors, while the latter was used to explore the detection of circulating tumor cells; these cells are shed by tumors into the bloodstream and are scarce, but may provide clues needed for disease monitoring.
In a proof of concept, the team used the triple-negative breast cancer cell line MDA-MB-436 to simulate circulating tumor cells and employed terbium-ion-modified vesicles carrying a fluorescent-signal precursor for recognition and signal amplification. After adding a small number of model cancer cells to mouse whole blood, the researchers analyzed the samples using a single-color flow cytometer. The results showed that the system could identify a single added model cancer cell against the vast background of red and white blood cells in more than 10 milliliters of blood. Detection performance also varied correspondingly with different numbers of added cells, although the signal tended to become saturated at higher numbers.
This is still not a blood test that can be used directly in patients. The circulating tumor cells in the experiment were cultured cells artificially added to mouse blood, rather than the more phenotypically diverse cells that arise naturally in patients with cancer; the study abstract also did not provide evidence from large clinical samples, validation across cancer types, the long-term safety of rare-earth ions, or consistency in batch manufacturing. As blood volume increases, large numbers of peripheral blood mononuclear cells may also impede contact between vesicles and target cells.
To develop this further into a diagnostic tool, researchers must demonstrate that it can distinguish vesicles or cells originating from tumors, inflammation, and normal tissues in actual patient samples, and establish reproducible sensitivity, specificity, and clinical interpretation thresholds. As for drug delivery, a more than 25-fold increase in in vitro interaction cannot yet be equated with tumor accumulation or therapeutic efficacy in the human body; the distribution and clearance of vesicles after entering circulation, ion stability, and exposure of non-target tissues are all questions that must be answered before translation.